Cardiol Therapeutics Inc.

11/03/2026 | Press release | Distributed by Public on 11/03/2026 16:17

Consent of Borden Ladner Gervais LLP (Form 6-K)

Consent of Borden Ladner Gervais LLP

We hereby consent to the reference to our name under the headings "Documents Filed as Part of the U.S. Registration Statement" and "Legal Matters," and to the reference to our name and use of our opinions under the headings "Eligibility for Investment" and "Certain Canadian Federal Income Tax Considerations," in the prospectus supplement dated November 3, 2026 relating to the issuance by Cardiol Therapeutics Inc. of Class A common shares, which forms part of the Registration Statement on Form F-10 (File No. 333-298852).

In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended.

/s/ Borden Lander Gervais LLP
Borden Ladner Gervais LLP
Cardiol Therapeutics Inc. published this content on November 03, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 03, 2026 at 22:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]